Bibliografia
1. Baldamus C et al. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008;25(11):1215-28
2. Brinks V et al. Quality of Original and Biosimilar Epoetin Products. Pharm Res 2011;28:386-393
3. Committee for Human Medicinal Products (CHMP). Guidance on biosimilar medicinal products containing recombinant erythropoietins. EMEA/CHMP/94526/2005 - CMP/BMPW/246511/05
4. Jommi C. PharmacoEconomics – Italian Research Articles 2010;12 (1):17-31
5. Kirkov V et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alpha. 1st Communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers. Arzneimittel- Forschung. 02/2008; 58(5):215-9
6. Kirkov V et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alpha. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers. Arzneimittel-Forschung. 02/2008; 58(5):220-4
7. Krivoshiev S et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Current Medical Research and Opinion 2008;24(5):1407-1415
8. Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology– a single-dialysis center experience. Clinical Nephrology 2011;75(1): 59-62 Ongoing study (411-54-04-46-0000) – Interim report.
9. Praditpornsilpa K. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney International 2011;80: 88–92
10. Schellekens H. Assessing the bioequivalence of biosimilars. The Retacrit® case. Drug Discovery Today 2009;14(9/10)
11. Wizemann V, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alpha in the maintenance phase of renal anaemia therapy. Curr Med Res Opin. 2008;24(3):625-37
|